ZAMBON
20.2.2020 07:02:04 CET | Business Wire | Press release
Zambon , a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, and Breath Therapeutics, a Zambon company , specializing in advanced inhaled therapeutics for severe respiratory diseases, announced today the initiation of the BOSTON-4 phase 2 multi-center clinical study of Liposomal Cyclosporine A for Inhalation (L‑CsA‑i) for the treatment of bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell transplant (alloHSCT). Additionally, the BOSTON-3 open-label extension study has been initiated and is open to eligible participants who complete the BOSTON‑1 and ‑2 phase 3 studies currently underway to evaluate L‑CsA‑i for the treatment of BOS following lung transplantation.
Anne Bergeron, MD, PhD, Prof, Hôpital Saint Louis, Paris said, “Bronchiolitis obliterans syndrome is the primary noninfectious pulmonary complication in patients who undergo allogeneic HSCT. Despite increased overall survival of alloHSCT patients over the last 20 years, there has been no significant therapeutic progress in the management of bronchiolitis obliterans syndrome, which remains a major prognostic factor in allogeneic HSCT. New directed therapies are urgently needed in the treatment of BOS. With successful development and regulatory approvals, L‑CsA‑i has the potential to become the first therapy for patients who develop this debilitating and fatal condition.”
Noreen R. Henig, MD, Chief Medical Officer at Breath Therapeutics, a Zambon company, stated, "We are pleased with the significant advancements we’ve achieved in the development of L‑CsA‑i for the treatment of BOS. The robust BOSTON development plan will provide essential information about the safety and efficacy of L-CsA-i for most patients suffering from BOS. With BOSTON‑1, -2, -3, and -4, we focus on two populations with a high incidence and prevalence of BOS – patients with BOS following lung transplant or BOS following alloHSCT. Our BOSTON‑1 and ‑2 pivotal studies are well underway and, with the initiation of BOSTON-3 and -4, we are one step closer in realizing our vision of bringing L‑CsA‑i to patients with BOS.”
BOSTON-4, a prospective, single-blind randomized study will assess the safety, tolerability, pharmacokinetics (PK), and exploratory efficacy and quality of life of L‑CsA‑i for the treatment of BOS in adult alloHSCT recipients. Twenty-four patients are expected to be enrolled at up to 20 centers in Germany, France, and Spain. Patients will be randomly allocated to receive either L‑CsA‑i plus standard-of-care (SOC), or liposomal placebo plus SOC for up to 12 weeks. L‑CsA‑i and placebo will be administered via the Investigational eFlow® Technology nebulizer system (PARI). Additional information is available at www.clinicaltrials.gov . (NCT04107675 )
BOSTON-3, an open-label extension study, offers eligible participants who complete the BOSTON‑1 or BOSTON‑2 phase 3 studies the opportunity to receive treatment of L‑CsA‑i plus SOC regardless of the randomization arm in the prior studies. The primary endpoint is change in forced expiratory volume (FEV1 ) (mL) from baseline to week 24. The study is being conducted at the same leading lung transplant centers in eight countries as the pivotal studies.
BOSTON‑1 and ‑2 phase 3 studies were initiated in March 2019 to evaluate the efficacy and safety of L‑CsA‑i in adults with BOS following a single lung (BOSTON‑1) or double lung (BOSTON‑2) transplantation. The primary endpoint is change in FEV1 (mL) from baseline to week 48 and key secondary endpoints will include mean change in FEV1 /FVC (forced vital capacity) and time to progression of BOS. For additional information about the BOSTON‑1, ‑2 and ‑3 studies, visit clinicaltrials.gov (B‑1 NCT03657342 ) (B‑2 NCT03656926 ) (B‑3 NCT04039347 )
L‑CsA‑i has received orphan drug designation for the treatment of BOS from the US Food and Drug Administration and European Medicines Agency.
Bronchiolitis Obliterans Syndrome (BOS)
Bronchiolitis Obliterans Syndrome (BOS ), also known as obliterative bronchiolitis (OB), is caused by T‑cell mediated inflammation that leads to blockage of bronchioles, the small and medium airways in the lungs, resulting in respiratory failure and death. BOS most commonly affects people who have received lung or allogeneic hematopoietic stem cell transplant, although it is also associated with autoimmune disease and exposure to environmental contaminants. Based on 2019 company market research, an estimated 30,000 lung transplant and alloHSCT recipients worldwide are affected by BOS.1
Liposomal Cyclosporine A for Inhalation (L-CsA-i)
Liposomal Cyclosporine A for Inhalation (L‑CsA‑i) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L‑CsA‑i is administered via a drug-specific Investigational eFlow® Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver L‑CsA‑i to the site of disease in the lung.
BOSTON Clinical Development Program
L‑CsA‑i is being evaluated for the treatment of BOS in patients age six and older. Five clinical trials are currently ongoing or planned. BOSTON-1 and BOSTON-2 are pivotal Phase 3 studies of adults with BOS following lung transplantation. BOSTON‑3 is an open-label extension study for eligible study participants who complete BOSTON‑1 or BOSTON‑2. BOSTON-4 is a safety and exploratory efficacy study and will be the first trial of L‑CsA‑i in adults with BOS following allogeneic hematopoietic stem cell transplant. BOSTON‑5 is a safety study in pediatric patients with BOS.
About Zambon S.p.A.
Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. Based on a valuable heritage and strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality healthcare solutions.
Zambon products are commercialized in 87 countries. The company has 20 subsidiaries in three different continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, China and Brazil. The company today has a strong focus on the treatment of rare diseases and specialties, on top of respiratory, pain management and women’s care. Zambon was established in 1906 in Italy and today counts 2,500 employees all over the world. For further information, please visit www.zambon.com
About Breath Therapeutics, a Zambon company
Founded in 2016, Breath Therapeutics is a biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with high unmet medical need. The company’s proprietary drug formulation has been specifically designed for inhaled administration with exclusively licensed, high performance nebulizer technology. L‑CsA‑i is advancing in clinical trials for the treatment of BOS, a rare and devastating lung disease with no currently approved treatments. In July 2019, Breath Therapeutics was acquired by Zambon S.p.A, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. Breath Therapeutics has offices in Munich, Germany and Menlo Park, California. For more information, please visit www.breath-therapeutics.com .
-------------------------
L‑CsA‑i and the eFlow® for L-CsA-i are investigational and their safety and efficacy have not been established for the uses described here.
Reference:
1. Data on File, Breath Therapeutics, a Zambon company, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005806/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
